DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.

Niels Herluf PaulsenFie VojdemanStig Ejdrup AndersenTroels Korshøj BergmannMarianne EwertzPeter PlomgaardMorten Rix Hansen Peter Skov EsbechPer PfeifferCamilla QvortrupPer Damkier

Published in: Basic & clinical pharmacology & toxicology (2022)

The evidence supporting either DPYD genotyping or DPD phenotyping as pre-treatment tests to reduce 5-FU toxicity is poor. Further evidence is still needed to fully understand and guide clinicians to dose by DPD activity.

Keyphrases

high throughput
palliative care
genome wide
oxidative stress
single cell
genetic diversity
high density